Epistem today provides an update regarding the Company's share investment plan, details of which were announced on 13 July 2009.
As a result of the subscription for Partnership Shares and the award of Matching Shares, the executive Directors have each increased their beneficial interest in the Company by 198 ordinary shares of 1.5p each. These shares were acquired on 31 January 2011 and 1 March 2011 at prices of 388p and 380p respectively.
The current beneficial interests of the executive Directors are set out below:
Matthew Walls 7,984 (0.10%)
Dr Catherine Booth 982,339 (12.38%)
Dr Ged Brady 2,339 (0.03%)
Dr Jeffrey Moore 16,839 (0.21%)
John Rylands 192,237 (2.42%)
For further details please contact:
Matthew Walls, CEO +44 161 606 7258
John Rylands, Finance Director +44 161 606 7244
Peel Hunt LLP
James Steel / Vijay Barathan +44 20 7418 8900
This information is provided by RNS
The company news service from the London Stock Exchange
Datafeed and UK data supplied by NETbuilder and Interactive Data.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk!
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.